Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).

撰文 | 唐东豪   责编 | 周叶斌在儿童肿瘤中，原发性肝癌（PLC）相对罕见，仅占所有儿童癌症的0.5%至1.5%。主要包括肝母细胞瘤（HB）和肝细胞癌（HCC）。而一种名为复合型肝细胞胆管癌（Combined ...

Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

Hepatocellular cancer, the most common form of primary liver cancer, is the fastest rising cause of cancer-related deaths in the United States. Texas has the highest incidence rates of HCC in the ...

Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – – Antitumor ...

Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).

Researchers at Mount Sinai have achieved a significant breakthrough in treating hepatocellular carcinoma (HCC), the most ...

SBRT showed superiority over radiofrequency ablation in local progression-free survival and tumor control in small HCC but ...

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”) ...